A biotechnology economy is usually described by its capital and its facilities, because both are easy to count. The deeper measure is whether its companies own technology that others want. On that measure the Gulf is at an early stage, and the opportunity ahead is clear.
What the company base looks like
At the top of A7i's companies dataset sit the government-owned platforms: Lifera and SaudiBio in Saudi Arabia, and Mubadala Bio, Arcera, M42 and PureHealth in the UAE. These are the largest and most capable organisations in the region's life sciences. They were established by sovereign investors as instruments of policy, which gives them scale and mandate from the outset.
Alongside them sits a layer of founded companies. Julphar, manufacturing in Ras Al Khaimah since 1980, is among the longest established. WAYAKIT, a KAUST spinout producing biotechnology-based disinfectants, already has foreign customers. Many of the newer companies are early-stage, and A7i tracks them through the 2025 cohort of the Saudi Biotechnology Accelerator, a government-backed programme that selected 62 companies across therapeutics, diagnostics, biomanufacturing, medical technology, digital health and green biotechnology.
What a cohort tells us
Roughly twenty of those 62 are Saudi-founded. A7i records them because the distribution is informative: the domestic cohort clusters in diagnostics, artificial intelligence platforms and agricultural biotechnology rather than therapeutics. Selection is the first public milestone for each of them. Funding rounds, preclinical data, registered trials and patents are the milestones that follow, and A7i adds each one to the record as it is published.
Cohort membership shows that a committee found the idea credible, and it marks the starting point of each company's public record.
The intellectual property opportunity
Owned, published patent positions are the next milestone across the tracker, the sovereign platforms included. Lifera manufactures under transferred technology. Mubadala Bio produces biologics under licence from an Argentine company. Arcera commercialises an extensive portfolio.
This is the central structural fact about Gulf biotechnology at the moment. The region has built the capacity to make advanced products invented elsewhere. That is a legitimate and valuable industrial position, and it is the position most manufacturing economies occupy on their way to owning technology. Making and owning are distinct stages, and telling them apart shows exactly where the next value will be created.
The programme to watch is the CAR-T therapy developed at King Faisal Specialist Hospital and Research Centre, which reached an SFDA-approved Phase I trial in August 2025. That is a Gulf-originated asset moving through a Gulf regulator. It is currently the clearest instance in A7i's datasets of the region creating its own technology.
What comes next in the research
The Saudi Authority for Intellectual Property publishes grant data, and analysing it is on A7i's research list. University technology transfer offices operate at KAUST and elsewhere, and licensing outcomes, as they are published, will add a further layer. Both will materially enrich this article. The position described here reflects the published evidence, and the record will grow as that evidence does.